PMID- 34740995
OWN - NLM
STAT- MEDLINE
DCOM- 20220201
LR  - 20220201
IS  - 1945-4589 (Electronic)
IS  - 1945-4589 (Linking)
VI  - 13
IP  - 21
DP  - 2021 Nov 5
TI  - Decoding the chemical composition and pharmacological mechanisms of Jiedu Tongluo 
      Tiaogan Formula using high-performance liquid chromatography coupled with network 
      pharmacology-based investigation.
PG  - 24290-24312
LID - 10.18632/aging.203679 [doi]
AB  - Type 2 diabetes mellitus (T2DM), a chronic low-grade inflammatory disease with 
      high morbidity and mortality, is a serious threat to public health. Previously we 
      demonstrated that a traditional Chinese medicine formulation, Jiedu Tongluo 
      Tiaogan Formula (JDTL), exerted a favorable hypoglycemic effect due to unknown 
      molecular mechanisms involving interactions among JDTL compounds and various 
      cellular components. This study aimed to explore JDTL mechanisms for alleviating 
      hyperglycemia using an integrated strategy incorporating system pharmacology, 
      bioinformatics analysis, and experimental verification. This strategy entailed 
      initial elucidation of JDTL chemical composition using fingerprint analysis via 
      high performance liquid chromatography (HPLC). Next, functions of putative shared 
      target genes and associated pathways were deduced using GO and KEGG pathway 
      enrichment and molecular docking analyses. Ultimately, targets associated with 
      JTDL anti-T2DM effects were found to be functionally associated with biological 
      functions related to lipopolysaccharide and cytokine receptor binding. These 
      results implicated PI3K-Akt signaling pathway involvement in JDTL anti-T2DM 
      effects, as this pathway had been previously shown to play significant roles in 
      glucose and lipid metabolism-related diseases. Furthermore, addition of JDTL to 
      INS-1 and HepG2 cell cultures stimulated cellular mRNA-level and protein-level 
      expression leading to enhanced production of IRS1, Akt, and PI3K. In summary, 
      here JDTL bioactive ingredients, potential targets, and molecular mechanisms 
      underlying JDTL anti-T2DM effects were identified using a multi-component, 
      multi-target, and multi-channel analytical approach, thus providing an important 
      scientific foundation to facilitate development of new drugs mechanistic 
      strategies for preventing and treating T2DM.
FAU - Zhang, Qi
AU  - Zhang Q
AD  - Changchun University of Chinese Medicine, Changchun 130021, Jilin Province, P.R. 
      China.
FAU - Piao, Chunli
AU  - Piao C
AD  - Shenzhen Hospital, Guangzhou University of Chinese Medicine (Futian), Shenzhen 
      518000, Guangdong Province, P.R. China.
FAU - Jin, Wenqi
AU  - Jin W
AD  - Changchun University of Chinese Medicine, Changchun 130021, Jilin Province, P.R. 
      China.
FAU - Jin, De
AU  - Jin D
AD  - Guang'anmen Hospital, China Academy of Chinese Medical Science, Beijing 100700, 
      P.R. China.
FAU - Wang, Han
AU  - Wang H
AD  - Guang'anmen Hospital, China Academy of Chinese Medical Science, Beijing 100700, 
      P.R. China.
FAU - Tang, Cheng
AU  - Tang C
AD  - Changchun University of Chinese Medicine, Changchun 130021, Jilin Province, P.R. 
      China.
FAU - Zhao, Xiaohua
AU  - Zhao X
AD  - Shenzhen Hospital, Guangzhou University of Chinese Medicine (Futian), Shenzhen 
      518000, Guangdong Province, P.R. China.
FAU - Zhang, Naiwen
AU  - Zhang N
AD  - Shenzhen Hospital, Guangzhou University of Chinese Medicine (Futian), Shenzhen 
      518000, Guangdong Province, P.R. China.
FAU - Gao, Shengnan
AU  - Gao S
AD  - Shenzhen Hospital, Guangzhou University of Chinese Medicine (Futian), Shenzhen 
      518000, Guangdong Province, P.R. China.
FAU - Lian, Fengmei
AU  - Lian F
AD  - Guang'anmen Hospital, China Academy of Chinese Medical Science, Beijing 100700, 
      P.R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211105
PL  - United States
TA  - Aging (Albany NY)
JT  - Aging
JID - 101508617
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Diabetes Mellitus, Type 2/metabolism
MH  - *Drugs, Chinese Herbal/analysis/chemistry/pharmacology
MH  - Humans
MH  - Molecular Docking Simulation
MH  - Network Pharmacology/*methods
MH  - Protein Interaction Maps/drug effects
PMC - PMC8610129
OTO - NOTNLM
OT  - Jiedu Tongluo Tiaogan Formula
OT  - PI3K/Akt signaling pathway
OT  - network pharmacology
OT  - traditional Chinese medicine
OT  - type 2 diabetes mellitus
COIS- CONFLICTS OF INTEREST: The authors declare that they have no conflicts of 
      interest.
EDAT- 2021/11/07 06:00
MHDA- 2022/02/02 06:00
PMCR- 2021/11/15
CRDT- 2021/11/06 05:39
PHST- 2021/07/19 00:00 [received]
PHST- 2021/10/26 00:00 [accepted]
PHST- 2021/11/07 06:00 [pubmed]
PHST- 2022/02/02 06:00 [medline]
PHST- 2021/11/06 05:39 [entrez]
PHST- 2021/11/15 00:00 [pmc-release]
AID - 203679 [pii]
AID - 10.18632/aging.203679 [doi]
PST - ppublish
SO  - Aging (Albany NY). 2021 Nov 5;13(21):24290-24312. doi: 10.18632/aging.203679. 
      Epub 2021 Nov 5.